ArticleEULAR rheumatology open2026
Management of mucocutaneous and joint involvement of Behçet's syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.EULAR rheumatology open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We aimed to update the evidence for the management of mucocutaneous and joint involvement of Behçet's syndrome (BS) to inform the 2025 update of European Alliance of Associations for Rheumatology (EULAR) recommendations. Methods: A systematic literature review was conducted to evaluate the benefits and harms of therapeutic interventions in patients with BS. All comparative studies were included, and in the absence of controlled studies for a specific intervention, noncomparative studies were also considered. We presented here the summary of the outcomes for mucocutaneous and joint involvement, overall disease activity and health-related quality of life (HRQoL). Results: Among the 7128 articles, 16 studies (7 randomised controlled trials [RCTs]) reported on mucocutaneous involvement, joint involvement, overall disease activity, or HRQoL. Apremilast was superior to placebo for oral ulcers in an RCT with low risk of bias (RoB). Few patients experienced genital ulcers, skin lesions, or arthritis during the 12 weeks. In the first head-to-head RCT with low RoB comparing adalimumab with infliximab, both drugs provided similar response rates for mucocutaneous manifestations, with a more rapid response observed with adalimumab. In other head-to-head RCTs, all with low RoB except for 1 with some concerns, the efficacy of immunosuppressive agents was confounded by concomitant glucocorticoid use for major organ involvement and by the small number of patients with active mucocutaneous manifestations. Conclusions: This systematic review supported the use of apremilast and tumour necrosis factor alpha inhibitors in patients with refractory mucocutaneous involvement and provided evidence for updating the 2025 EULAR Recommendations for the management of mucocutaneous and joint involvement of BS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.